Moors & Cabot, Inc. Crispr Therapeutics Ag Call Options Transaction History

Moors & Cabot, Inc.

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 14, 2024	BUY	$38.62 - $72.18 $46,344 - $86,616	1,200 New	1,200 $75,000
Q3 2021 Nov 05, 2021	SELL	$110.2 - $156.64 $231,420 - $328,944	-2,100 Closed	0 $0
Q2 2021 Aug 10, 2021	BUY	$100.84 - $161.89 $171,428 - $275,213	1,700 Added 425.0%	2,100 $32,000
Q1 2021 May 12, 2021	BUY	$110.72 - $210.04 $44,288 - $84,016	400 New	400 $11,000

499

56.8M

1.7M

1.8M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $4.05B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Moors & Cabot, Inc., based on Form 13F filings with the SEC.

Stay updated on Moors & Cabot, Inc. with notifications on news.